Teva settles Nuvigil litigation with Mylan
30 April 2012 | By Teva Pharmaceutical Industries Ltd
TEVA, has settled patent infringement litigation with Mylan Inc.'s ANDA for Teva’s wakefulness product NUVIGIL® (armodafinil) tablets...
List view / Grid view
News
BASF relocates production of Kolliphor TPGS to its Minden site
30 April 2012 | By
BASF will transfer the pharmaceutical production of KolliphorTM TPGS to its Minden facility...
Algeta and Sanofi extend research collaboration evaluating thorium-conjugated tumor-targeting antibody
30 April 2012 | By Citigate Dewe Rogerson
Algeta ASA announces that its research collaboration with Sanofi has been extended...
Switching to TWYNSTA® allows patients with uncontrolled hypertension on monotherapy to rapidly reach their blood pressure goals
29 April 2012 | By Boehringer Ingelheim
New data on TWYNSTA®...
Syrris Asia Chip Climate Controller – advanced microreactor temperature control
27 April 2012 | By kdm communications limited
Syrris offers the unique Asia Chip Climate Controller module for its revolutionary range...
Japan chooses Sanofi Pasteur for first enhanced Inactivated Polio Vaccine
27 April 2012 | By Sanofi
Approval of IMOVAX® POLIO by Japanese health authorities...
AstraZeneca needs new strategy after boardroom shake up – EP Vantage investigates
27 April 2012 | By AstraZeneca
As AstraZeneca PLC Chief Executive David Brennan steps down...
Catalent case study presented on achieving Biological Assay
Michael Merges, Director of Biopharmaceutical Support Services, and Michael Sadick, Ph.D., Senior Manager of Biopharmaceutical Characterization, Development and Analytical Services, Catalent Pharma Solutions, will be presenting “Bioassay Development Basics 101,” at the Biological Assay Development, Validation & Maintenance Conference in Boston, MA on Monday, April 30, 2012, at 1:30 p.m.
Merck wins U.S. ZETIA® (ezetimibe) / VYTORIN® (ezetimibe/simvastatin) patent infringement lawsuit
27 April 2012 | By Merck
"The court appropriately ruled that the patent for ZETIA and VYTORIN in the U.S. is valid..."
Novo Nordisk A/S expects to elect new chairman in 2013
27 April 2012 | By Novo Nordisk
Sten Scheibye has been elected to the Board of the Novo Nordisk Foundation...
GlaxoSmithKline receives European authorisation for Nimenrix™
27 April 2012 | By GlaxoSmithKline
The European Commission has granted marketing authorisation for Nimenrix...
Novartis drug Afinitor® approved by FDA as first medication to treat patients with non-cancerous kidney tumors associated with TSC
26 April 2012 | By Novartis
The FDA has approved Afinitor® tablets...
FDA approves Votrient® for treatment of patients with certain types of advanced soft tissue sarcoma
26 April 2012 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the U.S. FDA has approved Votrient® (pazopanib)...
Phenomenex creates centralized interactive resource for Kinetex core-shell HPLC/UHPLC column users
26 April 2012 | By Phenomenex Inc
Phenomenex Inc., introduces the “Kinetex Experience”...
More than 25,000 Novartis associates worldwide to volunteer for local causes in Community Partnership Day
26 April 2012 | By Novartis
Novartis associates to dedicate 200,000 work hours to supporting the local community...
